CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 66 enrolled
Drug / intervention
Fenofibrate 54mgdrug
Likely dose
Fenofibrate 54mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01280604
NCT01280604N/ACompleted
CompareCT.gov

Effects of Fenofibrate 160mg to 54mg Conversion on Triglyceride Levels in Patients on Statin Therapy

Kaiser Permanente·interventional·Posted Jan 21, 2011·Updated Jun 8, 2015

In Brief

A clinical study evaluating Fenofibrate 54mg for Hyperlipidemias. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The primary objective of this randomized trial is to measure the impact of converting patients on statin therapy from fenofibrate 160mg to 54mg per day compared to patients who continue fenofibrate 160mg per day for triglycerides.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperlipidemias
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 21, 2011
Enrollment StartOct 1, 2010
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.4 years ago

Interventions

Fenofibrate 54mgdrug

Subjects will receive fenofibrate 54mg daily.